Arcus Biosciences Inc (NYSE:RCUS) saw a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 1,590,000 shares, a decrease of 20.9% from the September 30th total of 2,010,000 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average daily volume of 245,600 shares, the days-to-cover ratio is currently 6.5 days.
NYSE:RCUS traded down $0.02 during mid-day trading on Thursday, hitting $7.97. The company’s stock had a trading volume of 54,579 shares, compared to its average volume of 171,959. Arcus Biosciences has a 1 year low of $6.30 and a 1 year high of $13.77. The stock has a market cap of $366.42 million, a price-to-earnings ratio of -5.57 and a beta of 0.99. The business’s fifty day moving average is $8.31 and its two-hundred day moving average is $8.46.
Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. The business had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $1.34 million. On average, equities research analysts predict that Arcus Biosciences will post -2 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP boosted its stake in shares of Arcus Biosciences by 17.3% during the 2nd quarter. GSA Capital Partners LLP now owns 16,243 shares of the company’s stock worth $129,000 after acquiring an additional 2,392 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of Arcus Biosciences during the 2nd quarter worth about $32,000. Meeder Asset Management Inc. boosted its stake in shares of Arcus Biosciences by 672.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock worth $46,000 after acquiring an additional 4,300 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Arcus Biosciences by 10.5% during the 3rd quarter. Rhumbline Advisers now owns 48,859 shares of the company’s stock worth $445,000 after acquiring an additional 4,660 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Arcus Biosciences by 32.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,315 shares of the company’s stock worth $195,000 after acquiring an additional 5,278 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Further Reading: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.